This Biotech Rags-to-Riches Story Could Deliver Blockbuster Profits

We love a good comeback story.

Especially when it involves a developmental-stage biotech firm...

Earlier this year, Trevena Inc. (Nasdaq: TRVN), a clinical-stage biopharmaceutical company received a double dose of bad news for its acute heart failure drug, TRV027, after it failed to meet either of its target outcomes (known as primary and secondary "endpoints" in drug-study jargon).

That news sent its stock down 18% for the day.

Leave a Reply

Your email address will not be published. Required fields are marked *


Some HTML is OK